Creative Planning Gilead Sciences, Inc. Transaction History

Creative Planning

  • $90.1 Billion
  • Q1 2024

A detailed history of Creative Planning transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Creative Planning holds 174,050 shares of GILD stock, worth $11.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
174,050
Previous 169,912 2.44%
Holding current value
$11.9 Million
Previous $13.8 Million 7.37%
% of portfolio
0.01%
Previous 0.02%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024
BUY
$71.58 - $87.29 $296,198 - $361,206
4,138 Added 2.44%
174,050 $12.7 Million
Q4 2023

Feb 14, 2024
BUY
$73.27 - $83.09 $1.24 Million - $1.41 Million
16,951 Added 11.08%
169,912 $13.8 Million
Q3 2023

Nov 16, 2023
BUY
$73.94 - $80.67 $56,711 - $61,873
767 Added 0.5%
152,961 $11.5 Million
Q2 2023

Jul 21, 2023
BUY
$76.01 - $86.7 $20,598 - $23,495
271 Added 0.18%
152,194 $11.7 Million
Q1 2023

May 15, 2023
BUY
$77.31 - $88.08 $359,568 - $409,660
4,651 Added 3.16%
151,923 $12.6 Million
Q4 2022

Feb 10, 2023
BUY
$62.32 - $89.47 $5,110 - $7,336
82 Added 0.06%
147,272 $12.6 Million
Q3 2022

Nov 03, 2022
BUY
$59.54 - $68.01 $376,888 - $430,503
6,330 Added 4.49%
147,190 $9.08 Million
Q2 2022

Aug 15, 2022
BUY
$57.72 - $65.01 $2.36 Million - $2.66 Million
40,951 Added 40.99%
140,860 $8.41 Million
Q1 2022

May 16, 2022
SELL
$57.92 - $72.58 $339,469 - $425,391
-5,861 Reduced 5.54%
99,909 $5.94 Million
Q4 2021

Feb 11, 2022
SELL
$64.88 - $73.64 $843,699 - $957,614
-13,004 Reduced 10.95%
105,770 $7.68 Million
Q3 2021

Nov 10, 2021
SELL
$67.69 - $73.03 $506,930 - $546,921
-7,489 Reduced 5.93%
118,774 $8.3 Million
Q2 2021

Aug 04, 2021
SELL
$63.47 - $69.35 $1.67 Million - $1.83 Million
-26,390 Reduced 17.29%
126,263 $8.69 Million
Q1 2021

Apr 30, 2021
SELL
$60.0 - $68.46 $3.46 Million - $3.94 Million
-57,596 Reduced 27.39%
152,653 $9.87 Million
Q4 2020

Jan 29, 2021
BUY
$56.65 - $64.55 $3.24 Million - $3.69 Million
57,180 Added 37.36%
210,249 $12.2 Million
Q3 2020

Nov 05, 2020
BUY
$62.1 - $78.08 $984,098 - $1.24 Million
15,847 Added 11.55%
153,069 $9.67 Million
Q2 2020

Jul 23, 2020
SELL
$72.34 - $84.0 $1.02 Million - $1.18 Million
-14,043 Reduced 9.28%
137,222 $10.6 Million
Q1 2020

May 05, 2020
SELL
$62.63 - $80.22 $2.06 Million - $2.64 Million
-32,902 Reduced 17.87%
151,265 $11.3 Million
Q4 2019

Jan 30, 2020
SELL
$61.62 - $67.78 $19,656 - $21,621
-319 Reduced 0.17%
184,167 $12 Million
Q3 2019

Nov 01, 2019
BUY
$62.51 - $69.0 $422,380 - $466,233
6,757 Added 3.8%
184,486 $11.7 Million
Q2 2019

Jul 26, 2019
BUY
$61.87 - $69.38 $185,671 - $208,209
3,001 Added 1.72%
177,729 $12 Million
Q1 2019

Apr 24, 2019
SELL
$62.53 - $70.05 $22,823 - $25,568
-365 Reduced 0.21%
174,728 $11.4 Million
Q4 2018

Feb 01, 2019
SELL
$60.54 - $79.0 $491,221 - $641,006
-8,114 Reduced 4.43%
175,093 $11 Million
Q3 2018

Oct 25, 2018
SELL
$71.28 - $78.92 $181,336 - $200,772
-2,544 Reduced 1.37%
183,207 $14.1 Million
Q2 2018

Jul 20, 2018
BUY
$64.88 - $75.68 $887,298 - $1.03 Million
13,676 Added 7.95%
185,751 $13.2 Million
Q1 2018

Apr 18, 2018
SELL
$72.84 - $88.8 $1.22 Million - $1.49 Million
-16,793 Reduced 8.89%
172,075 $13 Million
Q4 2017

Jan 17, 2018
BUY
$71.15 - $83.52 $70,723 - $83,018
994 Added 0.53%
188,868 $13.5 Million
Q3 2017

Oct 17, 2017
BUY
$72.11 - $85.47 $13.5 Million - $16.1 Million
187,874
187,874 $15.2 Million

Others Institutions Holding GILD

# of Institutions
1,884
Shares Held
1B
Call Options Held
8.71M
Put Options Held
8.02M
View Full List

About GILEAD SCIENCES, INC.

GILD Quotes by TradingView
  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $86B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email